BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 10, 2026
Home » Authors » Cormac Sheridan

Cormac Sheridan

Articles

ARTICLES

IsoTis Getting Foothold In U.S. Through Acquisition Of GenSci

June 4, 2003
By Cormac Sheridan
IsoTis SA unveiled a definitive merger agreement Tuesday to acquire GenSci Regeneration Sciences Inc., a Toronto-based orthobiologics firm emerging from Chapter 11 bankruptcy.(BioWorld International)
Read More

IsoTis Getting Foothold In U.S. Through Acquisition Of GenSci

June 4, 2003
By Cormac Sheridan
IsoTis SA unveiled a definitive merger agreement Tuesday to acquire GenSci Regeneration Sciences Inc., a Toronto-based orthobiologics firm emerging from Chapter 11 bankruptcy.(BioWorld International)
Read More

BioXell Closes Second Round Early, Raises EUR17M For Pipeline

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan
Medivir AB entered its largest drug development deal to date, a pact worth up to €86 million with GlaxoSmithKline plc to develop its HIV drug MIV-210. The news sent the Huddinge, Sweden-based company's share price soaring by almost 50 percent during trading on the Stockholm Stock Exchange last week, to close at SEK61 Friday. (BioWorld International)
Read More

Sidec Raises SEK10M For Protein Visualization, Eyes Breaking Even

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan

BioXell Closes Second Round Early, Raises EUR17M For Pipeline

May 28, 2003
By Cormac Sheridan

Sidec Raises SEK10M For Protein Visualization, Eyes Breaking Even

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan
Medivir AB entered its largest drug development deal to date, a pact worth up to €86 million with GlaxoSmithKline plc to develop its HIV drug MIV-210. The news sent the Huddinge, Sweden-based company's share price soaring by almost 50 percent during trading on the Stockholm Stock Exchange last week, to close at SEK61 Friday. (BioWorld International)
Read More
View All Articles by Cormac Sheridan

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Art concept for inflammation in the intestines

    Kymera’s IRF5 degrader shows potential in IBD treatment

    BioWorld Science
    At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing